“There is more afoot then is seen at first glanc
Post# of 148280
(Total Views: 770)
Posted On: 09/27/2020 8:59:48 AM
“There is more afoot then is seen at first glance.”
I doubt Incelldx’s business model hinges on the success of the cytokine test kits. Dr. BP has been extremely beneficial to CYDY, specifically to better understanding the MOA or leronlimab across multiple indications. Additionally, Dr. BP and Dr. Yo continue to support leronlimab as a treatment (Basically the only treatment) for the S/C population despite the deteriorated relationship between Dr. BP and CYDY.
So, to make assumptions that Dr. BP and Dr. Yo are downplaying the role of leronlimab in longhaulers in order to profit Incelldx seems ridiculous. Especially when you consider Incelldx’s recent PL-D1 patents and deals with legitimate biotechs that add to the companies revenues.
Can you imagine if a BO deal of Incelldx by CYDY had actually happened? We’d probably be on NASDAQ already.
I doubt Incelldx’s business model hinges on the success of the cytokine test kits. Dr. BP has been extremely beneficial to CYDY, specifically to better understanding the MOA or leronlimab across multiple indications. Additionally, Dr. BP and Dr. Yo continue to support leronlimab as a treatment (Basically the only treatment) for the S/C population despite the deteriorated relationship between Dr. BP and CYDY.
So, to make assumptions that Dr. BP and Dr. Yo are downplaying the role of leronlimab in longhaulers in order to profit Incelldx seems ridiculous. Especially when you consider Incelldx’s recent PL-D1 patents and deals with legitimate biotechs that add to the companies revenues.
Can you imagine if a BO deal of Incelldx by CYDY had actually happened? We’d probably be on NASDAQ already.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼